相关临床试验
332
30 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1998
进行中（未招募）
13
3.9%
已完成
217
65.4%
Enrolling By Invitation
6
1.8%
尚未招募
11
3.3%
招募中
30
9.0%
终止
6
1.8%
Unknown
47
14.2%
撤回
2
0.6%
暂无批准数据
- The CDC awarded a non-competitive $1.6 million grant to the University of Southern Denmark to conduct a randomized trial of neonatal hepatitis B vaccination involving over 14,000 newborns in Guinea-Bissau. - The study will assess all-cause mortality, severe morbidity, and long-term developmental outcomes of hepatitis B birth dose vaccination, entering an active scientific debate over non-specific vaccine effects. - Critics question the ethical rationale and methodology, noting that the Danish researchers' previous work has been challenged for over-interpreting findings and emphasizing secondary results that lose statistical significance after proper analysis. - The grant comes after ACIP voted to abandon the 34-year recommendation for universal newborn hepatitis B vaccination, despite evidence showing the practice has reduced childhood infections by 99% and prevented an estimated 90,100 deaths since 1991.
- Guinea-Bissau has suspended a $1.6 million Trump administration-funded hepatitis B vaccine study on newborns pending an ethical review after a six-person ethics committee failed to meet during the initial confirmation process. - The controversial randomized controlled trial would withhold proven hepatitis B vaccines from some newborns at significant infection risk, raising ethical alarms among public health experts. - The study was awarded to University of Southern Denmark researchers who have been cited by anti-vaccine activists and whose work has been questioned by leading public health experts. - The research is designed to track 14,000 newborns for death, illness and long-term developmental outcomes over five years, with most children followed for less than two years.
- A comprehensive analysis of 19 clinical trials involving 6,506 patients found tramadol provides only minimal pain relief that falls below clinically meaningful thresholds for chronic pain management. - The study revealed tramadol users face twice the odds of serious adverse events compared to placebo, with cardiac complications including chest pain, coronary artery disease, and congestive heart failure being primary concerns. - Researchers concluded that tramadol's potential harms likely outweigh its limited benefits, challenging its reputation as a safer opioid alternative and calling for minimized use. - The findings come amid America's ongoing opioid crisis, where 51.6 million adults live with chronic pain and doctors wrote 16 million tramadol prescriptions in 2023 alone.
- The RESTORE trial demonstrates that cognitive functional therapy (CFT) produces clinically important reductions in chronic low back pain and activity limitations that persist for three years. - CFT, delivered through seven sessions by specially trained physiotherapists, significantly outperformed usual care in reducing both pain intensity and physical activity limitations. - This represents the first large, high-quality study investigating long-term CFT outcomes, offering potential to markedly reduce the global burden of chronic back pain. - The biopsychosocial approach addresses physical, psychological and social factors while empowering patients with self-management skills and confidence to move.
- Men experience higher mortality rates from 13 of the top 20 global health conditions, with COVID-19 and heart disease showing 45% higher illness and death rates compared to women. - Women suffer disproportionately from non-fatal chronic conditions including musculoskeletal disorders, mental health problems, and headaches, with low back pain rates 33% higher than men. - Research indicates gender differences begin early in life, with road injuries affecting young males aged 10-24, while women's health conditions tend to intensify with age.
